Rigel Pharmaceuticals, Inc. - Common Stock (NQ:RIGL)

40.91 -4.80 (-10.49%)

Delayed Quote Updated: 9:47 AM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rigel Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Stands Out as a Top Growth Stock Candidate ↗

October 08, 2025

RIGL stock shows explosive growth with 5,567% EPS surge, soaring sales, and strong earnings surprises, fitting a proven growth investing model.

Via Chartmill

Rigel Pharmaceuticals Inc (NASDAQ:RIGL): An Affordable Growth Stock with Strong Upside Potential ↗

September 25, 2025

Rigel Pharmaceuticals (RIGL) offers high growth with a low P/E ratio. Strong EPS & revenue growth meet an affordable valuation, fitting the "affordable growth" investment profile.

Via Chartmill

Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday ↗

September 24, 2025

Via Benzinga

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Identified as a Top Value Stock with Strong Fundamentals ↗

September 23, 2025

Rigel Pharmaceuticals (RIGL) is a biotech stock with a compelling valuation, trading at a low P/E ratio. It boasts strong profitability, exceptional revenue & EPS growth, and solid financial health.

Via Chartmill

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

A Preview Of Rigel Pharmaceuticals's Earnings ↗

May 05, 2025

Via Benzinga

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Explosive Growth, Fits Navellier's 'Little Book' Strategy ↗

September 16, 2025

Rigel Pharmaceuticals shows explosive growth with 729% EPS growth, 106% revenue surge, and a 119% ROE, making it a top pick for momentum investors.

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines High Growth Momentum with Strong Technical Setup ↗

September 09, 2025

Discover RIGL stock's high growth momentum & strong technical setup. A top pick for investors seeking earnings acceleration & breakout potential.

Via Chartmill

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Affordable Growth Stock ↗

September 03, 2025

Rigel Pharmaceuticals (RIGL) is a GARP stock with explosive 729% EPS growth, trading at a deep discount with a P/E of just 7.11.

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A Deep Value Stock with Strong Fundamentals ↗

August 30, 2025

Rigel Pharmaceuticals (RIGL) presents a strong value investing case with a high valuation score, robust profitability, and impressive revenue growth, trading below intrinsic value.

Via Chartmill

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Emerges as a Top Growth Stock on Navellier's Screening Model ↗

August 26, 2025

Rigel Pharmaceuticals (RIGL) excels in a proven growth stock screening method, showing massive earnings growth, soaring revenue, and a high return on equity.

Via Chartmill

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Via Investor's Business Daily

Topics ETFs

In today's session, these stocks are experiencing unusual volume. ↗

August 12, 2025

Unusual volume stocks are being observed in Tuesday's session.

Via Chartmill

Unusual volume stocks in Monday's session ↗

August 11, 2025

Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

Rigel (RIGL) Q2 Revenue Jumps 176% ↗

August 06, 2025

Via The Motley Fool

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Aligns Perfectly with Louis Navellier’s Growth Investing Strategy ↗

August 05, 2025

Louis Navellier’s growth investing strategy highlights stocks like RIGL with strong earnings momentum, rising sales, and profitability, making it a standout pick for investors.

Via Chartmill

What to Expect from Rigel Pharmaceuticals's Earnings ↗

August 04, 2025

Via Benzinga

Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday ↗

May 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 06, 2025

Via Benzinga

Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday? ↗

March 05, 2025

The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points.

Via Benzinga

Topics Government Stocks

Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday? ↗

March 04, 2025

U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.

Via Benzinga

Topics World Trade

Earnings Scheduled For March 4, 2025 ↗

March 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 23, 2025

Via Benzinga

Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz ↗

January 14, 2025

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

Via Stocktwits

Dow Jumps Over 200 Points, Crude Oil Gains 1.5% ↗

December 24, 2024

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 08, 2024

Via Benzinga

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

October 16, 2024

From AscellaHealth, LLC

Via GlobeNewswire

RIGL Stock Earnings: Rigel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

RIGL stock results show that Rigel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.